Teva Pharmaceutical Industries Ltd. CEO Richard Francis responds to the 25% share price fall, stating that the question is no longer whether Teva will survive but whether it can grow more. Despite positive financial results for 2024, the company's profit guidance for 2025 disappointed the market. Francis remains optimistic about Teva's growth potential, emphasizing the company's investment in the business and its strategic plan based on growth, including an emphasis on branded drugs. He also highlights Teva's capabilities in developing branded products and its focus on biosimilars and generics.